A successful example of such a BsAb is blinatumomab, a CD3- and CD19-binding BsAb that bridges CD3 on T cells with CD19 overexpressed on leukemia cells and thereby acts as a T cell engager to direct the cytotoxic activity of T cells to the leukemia cells (5, 6). This evidence concerns the gene CD19 and leukemia.